Read and download full letter here
Conclusions:
The AKA respectfully requests that the FDA convene a public stakeholders meeting dedicated to the discussion of kratom products. Such a meeting would provide an invaluable opportunity for the FDA to engage directly with the kratom consumers most affected by potential regulatory actions, to hear from scientific and policy experts who have studied kratom, to evaluate legal experts views on the current excesses of the FDA’s abuse of authority in regulating kratom, and to better understand the experiences of those who use kratom as part of their health regimen as evidenced by numerous peer-reviewed published articles supporting the claims by consumers that kratom is helping them improve the quality of life they experience and, in many cases, actually saving their lives.
The stakes are high, and the outcomes of FDA-regulatory decisions pertaining to kratom products will have profound impacts on many lives. A public stakeholders meeting would help to ensure that these decisions are made with a full understanding of the potential benefits and risks, and that they are guided by current science, compassion, and a commitment to public health.
